Selskabets formål er at drive handels- og eksportvirksomhed med lægemidler samt, efter bestyrelsens skøn, at drive anden i forbindelse dermed stående virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 2.1 mia. | 32.7 mio. | 809.6 mio. | 345.3 mio. | 113 | |
CVR: 26256275
Secondary names: LUNDBECK MIDDLE EAST A/S
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Morten Bryde Hansen left the board
Henrik Agerbæk-Larsen left the board
Lorena Di Carlo joined the board
Lundbeck Export A/S exhibits a stable financial health with consistent revenue generation in the medicinal and healthcare products sector. Revenue has shown slight fluctuations, with 2025 reporting DKK 2.14 billion, a marginal decline from DKK 2.18 billion in 2024. Profitability has been inconsistent, with a notable drop in profit from DKK 84.9 million in 2022 to DKK 32.7 million in 2025, raising concerns about profit margins. The company's equity position remains solid at DKK 345.3 million, indicating a stable foundation, but the declining profit trend may signal challenges ahead in maintaining competitive positioning within the industry.
AI-generated summary
Companies in the same industry and area
CVR 43707795
CVR 35818790
CVR 39791447
CVR 40051481
CVR 33597037
companydata.dk